AgomAb Therapeutics NV - ADRs representing one common share. (AGMB)

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company developing disease-modifying therapies for immunology and inflammatory diseases, beginning with chronic fibrotic conditions. Its research targets the TGF-beta signaling pathway, a central driver of fibrosis, with the goal of halting or reversing tissue scarring and restoring organ function.

Its lead candidate, ontunisertib, is an oral, gut-restricted ALK5 inhibitor being developed for fibrostenosing Crohn's disease, a complication in which scarring narrows the intestine. A second clinical candidate is an inhaled ALK5 inhibitor for idiopathic pulmonary fibrosis, and the company also has earlier-stage discovery programs.

AgomAb was founded in 2017 and is headquartered in Belgium. Its American depositary shares trade on Nasdaq.